Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2023 16:00 ET | Source: Disc Medicine Inc

Disc Medicine to Participate in the Jefferies Healthcare Conference

WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
May 15, 2023 07:00 ET | Source: Disc Medicine Inc

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from open-label BEACON trial to be presented at the European Hematology Association (EHA) Congress in June 2023;...
May 11, 2023 10:15 ET | Source: Disc Medicine Inc

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

WATERTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
April 21, 2023 08:30 ET | Source: Disc Medicine Inc

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
April 13, 2023 11:00 ET | Source: Disc Medicine Inc

Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)

WATERTOWN, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
March 31, 2023 07:00 ET | Source: Disc Medicine Inc

Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update

Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2022 with approximately $194.6 million in cash and cash equivalentsInitiated two Phase 2 trials, AURORA and...
March 21, 2023 07:00 ET | Source: Disc Medicine Inc

Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

WATERTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
February 16, 2023 08:00 ET | Source: Disc Medicine Inc

Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

WATERTOWN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for...
February 14, 2023 06:30 ET | Source: Disc Medicine Inc

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

WATERTOWN, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...
February 08, 2023 16:00 ET | Source: Disc Medicine Inc

Disc Medicine to Participate in SVB Securities Global Biopharma Conference

WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...